01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
21:02 , Jun 27, 2019 |  BC Extra  |  Financial News

Syncona reaps tenfold return from Blue Earth exit

Returns from the sale of Blue Earth Diagnostics for $450 million will allow majority shareholder Syncona to reinvest in its maturing portfolio companies as they scale, and will also drive new company launches, the firm's...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Vitaros alprostadil regulatory update

Apricus said Vitaros alprostadil was approved to treat erectile dysfunction (ED) in Austria, Cyprus, the Czech Republic, Denmark, Finland, Greece, Iceland, Norway, Poland, Portugal, Romania and the Slovak Republic. In June 2013, Vitaros was approved...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

Sulfur hexafluoride lipid-type A microspheres regulatory update

FDA approved Lumason sulfur hexafluoride lipid-type A microspheres from Bracco as an ultrasound contrast agent. The product is indicated for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

Vitaros alprostadil regulatory update

Apricus said Belgium's Ministry of Social Affairs, Public Health and Environment approved Vitaros alprostadil to treat erectile dysfunction (ED). Vitaros was approved under Europe's decentralized procedure in June, with the Netherlands acting as the reference...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

Vitaros alprostadil regulatory update

On Dec. 19, 2013, Apricus said France's National Agency for Medicines and Health Products Safety (ANSM) approved Vitaros alprostadil to treat erectile dysfunction (ED). Vitaros was approved under Europe's decentralized procedure in June, with the...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Apricus Biosciences, Novartis sales and marketing update

On Dec. 16, 2013, Apricus and the Sandoz generics unit of Novartis added Austria, Belgium, Denmark, Finland, Iceland, Luxembourg, the Netherlands, Norway, Sweden and Switzerland to a February 2012 deal granting Sandoz rights to market...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Vitaros alprostadil regulatory update

Apricus said the Italian Medicines Agency (AIFA) approved Vitaros alprostadil to treat erectile dysfunction (ED). Vitaros was approved under the Europe's decentralized procedure in June, with the Netherlands acting as the reference state. Concerned member...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Apricus Biosciences, Laboratoires Majorelle sales and marketing update

Apricus granted Majorelle exclusive rights to market Vitaros alprostadil in France, Monaco and certain African countries. Apricus is eligible to receive up to $4 million in upfront and regulatory milestone payments and up to about...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Vitaros alprostadil regulatory update

Apricus said the German Federal Institute for Drugs and Medical Devices (BfArM) approved Vitaros alprostadil to treat erectile dysfunction (ED). Vitaros now has national approvals in 5 European countries, including Ireland, the Netherlands, Sweden and...